(Bloomberg) -- Nasdaq 100 Index futures fell on a report Donald Trump is preparing to sign an executive order that could threaten to penalize Facebook Inc., Google and Twitter Inc. for the way they moderate content on their sites.Contracts for June delivery on the Nasdaq 100 fell as much as 0.8%, before paring losses to 0.1% as of 2:50 p.m. in Tokyo. Trump’s upcoming executive order aims for federal regulators to review a law that spares tech companies from liability for comments and content posted by users, the Washington Post reported. Investor sentiment was also damped by deteriorating U.S.-China ties.“U.S. tech stocks are dropping on profit taking and risk aversion, as they are at the forefront of the U.S.-China cold war,” said Nader Naeimi, the head of dynamic markets at AMP Capital Investors Ltd. in Sydney. In addition, there is news that “Trump is preparing to sign an executive order that...
Roche plans to test if mixing its anti-inflammation drug Actemra with Gilead Sciences Inc's anti-viral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone, the Swiss drugmaker said on Thursday. Actemra and remdesivir are being used separately in some settings and clinical trials, with the former drug used to tackle massive immune reactions that sometimes occur in patients stricken with the new coronavirus and the latter aimed at interfering with viral replication....
Shares in PhaseBio Pharmaceuticals (PHAS) surged 82% in after-hours trading on Wednesday, after the company announced clearance of its investigational new drug (IND) application by the FDA under its Coronavirus Treatment Acceleration Program (CTAP).PhaseBio’s “VANGARD” trial will assess the efficacy and safety of its PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome. Approximately 210 patients will be targeted to be enrolled at approximately 20 sites across the US. The primary endpoint will measure days alive and free of respiratory failure.The patients will be treated with PB1046, a novel, once-weekly, subcutaneously-injected vasoactive intestinal peptide (VIP) receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. VIP is a neurohormone known to have anti-inflammatory effects, and importantly, has also been observed to have potent bronchodilatory and immunomodulatory effects in the respiratory system.PhaseBio now expects to begin dosing patients by the end of June...
Spot gold was up 0.6% at $1,719.08 per ounce by 0918 GMT, recovering from a two-week low of $1,693.22 touched in the previous session. U.S. gold futures rose 0.5% to $1,718.60. China's parliament approved a national security legislation for Hong Kong on Thursday, fuelling fears that could jeopardise its special autonomy and freedoms....
Spot gold was up 0.6% at $1,718.77 per ounce, as of 0544 GMT, after dropping to $1,693.22 on Wednesday. U.S. gold futures rose 0.5% to $1,717.80. "That's bad news for the globe as it spills over into trade- the impact on global growth, while the global economies are fragile, could be severe."...
Oil prices plunged on Thursday after U.S. industry data showed a surprise steep build in crude oil inventories, dampening hopes of a smooth recovery in demand as some countries begin to ease their way out of coronavirus lockdowns. The decline in oil benchmarks extended losses from Wednesday over uncertainty about Russia's commitment to deep output cuts ahead of a June 9 meeting of the Organization of the Petroleum Exporting Countries and its allies, a grouping dubbed OPEC+. U.S. West Texas Intermediate (WTI) crude futures were down 3%, or 98 cents, at $31.83 a barrel at 0709 GMT....
Oil prices slid for a second consecutive session on Thursday as U.S. industry data showed a steep and surprising build-up in crude stockpiles, dampening hopes of a smooth demand recovery as the world begins to ease its way out of coronavirus lockdowns. The decline extended losses from Wednesday on uncertainty about Russia's commitment to deep oil production cuts in the lead-up to a June 9 meeting of the Organization of the Petroleum Exporting Countries and its allies, dubbed OPEC+. U.S. West Texas Intermediate (WTI) crude futures were down 4.4%, or $1.44 at $31.37 a barrel at 0402 GMT after slipping as much as 5% to a low of $31.14 earlier in the session....